PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15297015-11	2004	These findings suggest that the balance between IL10 and IL6 release and the correlated p45 phosphorylation are important components of the Be-mediated immune response in healthy individuals.	Beryllium	140-142	interleukin 6	Homo sapiens	57-60	
11405518-2	2001	Beryllium induces interferon-gamma (IFN-gamma), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-10 (IL-10) from BAL cells.	Beryllium	0-9	interleukin 6	Homo sapiens	112-125	
11405518-2	2001	Beryllium induces interferon-gamma (IFN-gamma), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-10 (IL-10) from BAL cells.	Beryllium	0-9	interleukin 6	Homo sapiens	127-131	
9412570-0	1997	Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease.	Beryllium	0-9	interleukin 6	Homo sapiens	61-74	
11405518-11	2001	Compared to the unstimulated CBD PBMNs, beryllium stimulated significant IFN-gamma, TNF-alpha, IL-2, IL-6 and IL-10 production.	Beryllium	40-49	interleukin 6	Homo sapiens	101-105	
9412570-2	1997	We hypothesized that beryllium salts would stimulate bronchoalveolar lavage (BAL) cell release of tumor necrosis factor-alpha (TNF-alpha) and lnterleukin-6 (IL-6), and their soluble receptors, soluble TNF receptor I (sTNF RI), sTNF RII, and sIL-6R and that chronic exposure to antigen would increase production of soluble receptors in the serum and BAL fluid (BALF) of beryllium-sensitized and CBD patients.	Beryllium	21-30	interleukin 6	Homo sapiens	157-161	
9412570-2	1997	We hypothesized that beryllium salts would stimulate bronchoalveolar lavage (BAL) cell release of tumor necrosis factor-alpha (TNF-alpha) and lnterleukin-6 (IL-6), and their soluble receptors, soluble TNF receptor I (sTNF RI), sTNF RII, and sIL-6R and that chronic exposure to antigen would increase production of soluble receptors in the serum and BAL fluid (BALF) of beryllium-sensitized and CBD patients.	Beryllium	369-378	interleukin 6	Homo sapiens	157-161	
8179912-0	1994	Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta.	Beryllium	40-49	interleukin 6	Homo sapiens	143-156	
8933043-4	1996	We observed the beryllium-stimulated release of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-2 (IL-2), and interferon-gamma (IFN-gamma) but not interleukin-4 (IL-4).	Beryllium	16-25	interleukin 6	Homo sapiens	89-102	
8933043-4	1996	We observed the beryllium-stimulated release of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-2 (IL-2), and interferon-gamma (IFN-gamma) but not interleukin-4 (IL-4).	Beryllium	16-25	interleukin 6	Homo sapiens	104-108	
8179912-3	1994	We hypothesized that alveolar macrophages and bronchoalveolar lavage fluid from patients with beryllium disease and sarcoidosis would express increased levels of mRNA and proteins, respectively, for TNF-alpha, IL-1 beta, and IL-6 compared with those of normal individuals.	Beryllium	94-103	interleukin 6	Homo sapiens	225-229	
8179912-6	1994	In patients with beryllium disease (n = 23), we observed elevated macrophage mRNA expression for TNF-alpha and IL-6 when compared with that of normal subjects (n = 7).	Beryllium	17-26	interleukin 6	Homo sapiens	111-115	
8428540-0	1993	Increased TNF-alpha and IL6 mRNA expression by alveolar macrophages in chronic beryllium disease.	Beryllium	79-88	interleukin 6	Homo sapiens	24-27	
26929249-6	2016	Further studies indicated that CS-IVa-Be is an antagonist of IL6 receptor via directly binding to the IL6Ralpha with a Kd of 663 +- 74 nmol/L and the GP130 (IL6Rbeta) with a Kd of 1,660 +- 243 nmol/L, interfering with the binding of IL6 to IL6R (IL6Ralpha and GP130) in vitro and in cancer cells.	Beryllium	37-40	interleukin 6	Homo sapiens	61-64	
26929249-6	2016	Further studies indicated that CS-IVa-Be is an antagonist of IL6 receptor via directly binding to the IL6Ralpha with a Kd of 663 +- 74 nmol/L and the GP130 (IL6Rbeta) with a Kd of 1,660 +- 243 nmol/L, interfering with the binding of IL6 to IL6R (IL6Ralpha and GP130) in vitro and in cancer cells.	Beryllium	37-40	interleukin 6	Homo sapiens	102-105